SCHEMBL15375431

SCHEMBL15375431

CCCCNC(=O)C(OCCCC)c1ccccc1COc1cc(C)ccc1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.41
HTT P42858 1/20 0.41
ALDH1A1 P00352 3/20 0.40
TSHR P16473 3/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
HPGD P15428 1/20 0.38
NR1H4 Q96RI1 1/20 0.38
REN P00797 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
PPARA Q07869 3/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
TTR P02766 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C8 P10632 1/20 0.36
CHRM1 P11229 1/20 0.36
CYP2C9 P11712 1/20 0.36
ADRA1A P35348 1/20 0.36
PPARG P37231 1/20 0.36
HTR2B P41595 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15402180 0.90 LMNA (0.42) LMNAHTTALDH1A1TSHRMEN1
SCHEMBL15375535 0.90 TSHR (0.41) HTTALDH1A1TSHRMEN1KMT2A
SCHEMBL15375646 0.83 LMNA (0.42) LMNAHTTALDH1A1TSHRMEN1
SCHEMBL1539452 0.80 TSHR (0.40) LMNAHTTALDH1A1TSHRMEN1
SCHEMBL7524475 0.80 SMN1; SMN2 (0.44) LMNAHTTALDH1A1TSHRMEN1
SCHEMBL15401618 0.80 PTGDR2 (0.45) LMNAHTTALDH1A1TSHRMEN1
SCHEMBL15401631 0.78 TSHR (0.44) LMNAHTTALDH1A1TSHRMEN1
SCHEMBL16858325 0.75 SMN1; SMN2 (0.45) LMNAHTTALDH1A1TSHRMEN1
SCHEMBL29371189 0.75 SMN1; SMN2 (0.45) LMNAHTTALDH1A1TSHRMEN1
SCHEMBL230669 0.75 SMN1; SMN2 (0.45) LMNAHTTALDH1A1TSHRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2682382-B1 Method for Producing Phenylacetamide Compound SUMITOMO CHEMICAL CO (JP) 2016-11-23 EP disclosed
EP-2662352-B1 Method for Producing Phenylacetamide Compound SUMITOMO CHEMICAL CO (JP) 2016-11-09 EP disclosed
EP-2397459-B1 METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND SUMITOMO CHEMICAL CO (JP) 2015-12-16 EP disclosed
EP-2682382-A2 Method for Producing Phenylacetamide Compound Sumitomo Chemical Company, Limited (JP) 2014-01-08 EP disclosed
US-8624062-B2 Method for producing phenylacetamide compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-01-07 US disclosed
EP-2662352-A2 Method for Producing Phenylacetamide Compound Sumitomo Chemical Company, Limited (JP) 2013-11-13 EP disclosed
EP-2397459-A1 METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND Sumitomo Chemical Company, Limited (JP) 2011-12-21 EP disclosed
US-20110295035-A1 METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110295035-A1 METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND MRPL21, AADAC, ARSA LMNA 4708/4885HTT 1507/4885ALDH1A1 1164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.